Ginkgo Bioworks Completes Divestiture of Biosecurity Segment, Secures 20% Equity Stake in Tower Biosecurity
Ginkgo Bioworks Holdings, Inc. (DNA) announced the completion of the previously disclosed transaction to divest its Biosecurity segment on April 3, 2026. The company's wholly-owned subsidiary, Ginkgo Bioworks, Inc., contributed substantially all operations of Ginkgo Biosecurity, LLC to Tower Biosecurity, Inc. (also known as Perimeter Systems, Inc.). In exchange, Ginkgo received shares representing approximately 20% of Tower Biosecurity's fully diluted equity, indicating a strategic partnership or continued interest in the divested entity's future. This divestiture meets the criteria for discontinued operations under Accounting Standards Codification 205-20, necessitating the inclusion of unaudited pro forma financial statements for the years ended December 31, 2025, 2024, and 2023 in the current report.
Key Highlights
- Ginkgo Bioworks Holdings, Inc. completed the divestiture of its Biosecurity segment on April 3, 2026.
- The transaction involved Ginkgo Bioworks, Inc. (a subsidiary) contributing all equity interests of Ginkgo Biosecurity, LLC to Tower Biosecurity, Inc. (also known as Perimeter Systems, Inc.).
- In exchange for the Biosecurity segment, Ginkgo received shares of common stock representing approximately 20% of Tower Biosecurity's issued and outstanding equity on a fully diluted basis.
- The transaction was executed under a Stock Purchase Agreement dated February 26, 2026.
- As a result of the completion, the Company will account for the Biosecurity segment as discontinued operations under Accounting Standards Codification 205-20.
- Unaudited pro forma Condensed Consolidated Balance Sheet as of December 31, 2025, and Statements of Operations for the years ended December 31, 2025, 2024, and 2023 will be included in the filing.